High-risk CLL patients benefit from three-drug therapy: Study
If you have chronic lymphocytic leukemia (CLL), you may be wondering about your treatment options. A new study has found that three-drug therapy may be the best option for high-risk patients.
The study, which was published in the journal Blood, looked at data from over 1,000 CLL patients. The researchers found that patients who received three-drug therapy had a lower risk of disease progression and death than those who received two-drug therapy.
Three-drug therapy is more expensive and more toxic than two-drug therapy, but the benefits may be worth it for high-risk patients. If you have CLL, talk to your doctor about whether three-drug therapy is right for you.
Group Media Publications
General News Platform – https://ihtlive.com/
Entertainment News Platforms – anyflix.in
Construction Infrastructure and Mining News Platform – https://cimreviews.com/
Podcast Platforms – https://anyfm.in/